Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Liver Diseases × Ribavirin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 7 Hepatitis C 5 Recurrence 4 Hepatitis C, Chronic 4 Neoplasms 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Follicular 3 Leukemia, Myeloid, Acute 3 Respiratory Tract Infections 2 Lymphoma, Mantle-Cell 2 Infections 2 Head and Neck Neoplasms 2 Breast Neoplasms 2 Wilms Tumor 1 Testicular Neoplasms 1 Teratoma, Testicular 1 Teratoma 1 Seminoma 1 Respiratory Syncytial Virus Infections 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Pneumonia 1 Neuroblastoma 1 Neoplasms, Squamous Cell 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Melanoma 1 Malignant Solid Tumor 1 Lymphoma, T-Cell, Cutaneous 1

Interventions

Sorafenib 5 Blood Specimen Collection 4 pembrolizumab 2 lenvatinib 2 ledipasvir, sofosbuvir drug combination 2 halofantrine 2 camrelizumab 2 atezolizumab 2 Liver Transplantation 2 Immunotherapy 2 Control Groups 2 Bevacizumab 2 trifluridine tipiracil drug combination 1 trametinib 1 toripalimab 1 titanium silicide 1 tislelizumab 1 sintilimab 1 rubitecan 1 repotrectinib 1 pevonedistat 1 ozanimod 1 linifanib 1 genexol-PM 1 gadolinium ethoxybenzyl DTPA 1 fluorocholine 1 fisogatinib 1 ficlatuzumab 1 durvalumab 1 belinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡